| Official Full Name |
Recombinant Human Granulocyte Colony Stimulating Factor (rHuG-CSF) |
| Squence |
 |
| Amino Acid Sequence |
TPLGPASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL GHSLGIPWAP LSSCPSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAF ASAFQRRAGG VLVASHLQSF LEVSYRVLRH LAQP |
| 别名 |
CSF-3, MGI-1G, GM-CSF beta, Pluripoietin |
| Accession Number |
P09919 |
| GeneID |
1440 |
| Summary |
Granulocyte colony stimulating factor (G-CSF) is a pleiotropic cytokine. It is mainly produced by monocytes and macrophages upon activation by endotoxin, TNF-alpha and IFN-gamma. Besides, many other cell types can secreted this protein after LPS, IL-1 or TNF-alpha activation, which are fibroblasts, endothelial cells, astrocytes and bone marrow stromal cells. Various carcinoma cell lines and myeloblastic leukemia cells can express G-CSF constitutively. G-CSF is cytokine that acts in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. In addition it may function in some adhesion or recognition events at the cell surface.
In humans, two distinct cDNA clones for G-CSF, encoding 207 and 204 amino acid (a.a.) precursor proteins, have been isolated. Both proteins have a 30 a.a. signal peptide and have identical amino acid sequences except for a three a.a. insertion (deletion) at the 35th a.a. residue from the N-terminus of the mature protein. Human G-CSF is 73 % identical at the amino acid level to murine G-CSF and the two proteins show species cross-reactivity. |
| Source |
Escherichia coli. |
| 分子量 |
Approximately 18.7 kDa, a single non-glycosylated polypeptide chain containing 174 amino acids. |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine NFS-60 cells is less than 0.1 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg. |
| Appearance |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation |
Lyophilized from a 0.2 um filtered concentrated solution in 10mM sodium acetate buffer, containing 5 % trehalose, pH 4.0. |
| Endotoxin |
Less than 1 EU/ug of rHuG-CSF as determined by LAL method. |
| Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| References |
|
| SDS-PAGE |
 |
| Safety Data Sheet (SDS) Download |
Click to download |
| Technical Data Sheet (TDS) Download |
Click to download |
